Skip to main content
. Author manuscript; available in PMC: 2017 Jun 26.
Published in final edited form as: Mol Cancer Ther. 2010 Jul 6;9(7):2026–2036. doi: 10.1158/1535-7163.MCT-10-0238

Figure 2.

Figure 2

Degrasyn inhibits constitutively activated pSTAT3 and NF-κB in MCL cells. (A) Cell extracts purified from six MCL cell lines (top panel), six primary MCL cells (middle panel) and control normal (unstimulated) and activated B cells (CD154 plus IgM) (bottom panel) were subjected to Western blotting for STAT3, pSTAT3 (ser-727), and actin (loading control). (B) Mino MCL cells were treated with dose-dependent (0-5 μM) of degrasyn for 24 h (top panel) or time-dependent (0-12 h) with 5 μM of degrasyn (bottom panel). Cells extracts from the cells were purified and analyzed by Western Blot for pSTAT3, STAT3 and Actin. (C) Western blots from part B (above) were stripped and reblotted for pIκBα and IκBα. (D) Mino cells were co-transfected with the 6xNF-κB-luc reporter plasmid and β-gal reporter plasmid and then treated with degrasyn or bortezomib (BZ), as a control, for the indicated times. Luciferase activity was measured and normalized according to β-gal activity. The data shown are the means and ranges of triplicate samples of three independent experiments. Error bars represent standard deviation.